Pricing and reimbursement
AIFA intervenes in the governance of pharmaceutical expenditure by negotiating the price of medicinal products and managing the National Pharmaceutical Formulary (PFN).
In addition, AIFA monitors the appropriateness of use of medicines through the development, management and analysis of registers and consumption data.
It periodically reviews the Notes, which are regulatory tools that define the eligibility for reimbursement of some medicinal products and are updated on the basis of new scientific evidence and the needs of daily medical practice on the national territory.
Every month, the Agency also publishes the updated transparency lists, which are the lists of medicinal products whose patent coverage has expired, with the relative reference prices.
25/11/2024
15/11/2024
11/11/2024
11/11/2024
06/11/2024
15/10/2024
09/10/2024
09/10/2024
16/09/2024
22/08/2024
21/08/2024
13/08/2024
13/08/2024
09/08/2024
05/08/2024
01/08/2024
01/08/2024
25/07/2024
24/07/2024
18/07/2024
17/07/2024
15/07/2024
05/07/2024
27/06/2024
18/06/2024
17/06/2024
11/06/2024
07/06/2024
21/05/2024
21/05/2024
15/05/2024
17/04/2024
16/04/2024
10/04/2024
09/04/2024
27/03/2024
25/03/2024
18/03/2024